Features December 2010 Issue

Device Designed to Prevent Strokes Gets Widespread Use

Cleveland Clinic doctors developed a method of reducing blood clot formation in the left atrial appendage of the heart.

A device developed by Cleveland Clinic doctors to help eliminate blood clot formation in a small part of the heart is now available for widespread clinical application. Approval for the AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion system by the Food and Drug Administration was granted earlier this year and its commercial availability was launched this fall. Developed by Delos Cosgrove, MD, President and CEO of Cleveland Clinic, and A. Marc Gillinov, MD, Surgical Director of the Center for Atrial Fibrillation, the AtriClip is designed to eliminate blood flow from the left atrium to the left atrial appendage (LAA), a small sac-like structure attached to the atrium.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.